[CLSTR]
< Back to situations

[ORGANIZATION]

Galderma

Featured in 14 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

311 clusters · 1155 sources · last updated

Latest: GLP-1 receptor agonists linked to weight loss in peritoneal dialysis patients

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health, with some scientists suggest

[ACTIVE] [HEALTH] [US]

Atopic dermatitis monoclonal antibody clinical developments

2 clusters · 2 sources · last updated

Latest: Atopic dermatitis treatments show long-term efficacy in new clinical data

Clinical data released in October 2026 highlights long-term efficacy for monoclonal antibody treatments targeting atopic dermatitis and prurigo nodularis. Initial findings from the ARCADIA and OLYMPIA studies showed tha

[QUIET] [HEALTH] [CH] [US]

Galderma Nemluvio long-term efficacy data

2 clusters · 4 sources · last updated

Latest: Galderma reports three-year data for Nemluvio in atopic dermatitis

Galderma has released long-term efficacy and safety data from the ARCADIA study regarding its medication Nemluvio (nemolizumab) for treating moderate to severe atopic dermatitis. Initial reports indicated that the monoc

[QUIET] [HEALTH] [BA] [BR] [ES]

Industry shift from anti-aging to skin longevity and well-ag

12 clusters · 37 sources · last updated

Latest: Botox approach shifts toward anatomical restoration and natural expression

The beauty and wellness industry is undergoing a significant strategic and linguistic transition, moving away from the term ‘anti-aging’ in favor of ‘skin longevity.’ This shift is driven by advancements in longevity sci

Also covered in